MagnetisMM-1: Efficacy, Safety, and Tolerability of Subcutaneous Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma

CCO Conference Coverage of ASH 2021 with downloadable slides and experts’ commentaries of clinically relevant studies

John M. Burke, MD Amy E. DeZern, MD, MHS Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Mark A. Schroeder, MD Sujit Sheth, MD B. Douglas Smith, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 8, 2021

Commentary on considerations affecting therapy recommendations for patients with myeloma in the evolving treatment landscape, from Clinical Care Options (CCO)

Brian G.M. Durie, MD
Program Director Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD Released: December 7, 2021

Commentary from Dr. Julie Vose on how to select therapy for patients with EBV-positive PTLD, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 6, 2021

Interactive online tool with expert recommendations for assessing and managing adverse events associated with BTK inhibitors, from Clinical Care Options

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: December 6, 2021